Phase I/II Study of CaspaCIDe T Cells From an HLA-partially Matched Family Donor After Negative Selection of TCR Alpha Beta T Cells in Pediatric Patients Affected by Hematological Disorders

Trial Profile

Phase I/II Study of CaspaCIDe T Cells From an HLA-partially Matched Family Donor After Negative Selection of TCR Alpha Beta T Cells in Pediatric Patients Affected by Hematological Disorders

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Rivogenlecleucel (Primary) ; Rimiducid
  • Indications Haematological malignancies
  • Focus Adverse reactions; Registrational
  • Sponsors Bellicum Pharmaceuticals
  • Most Recent Events

    • 11 Sep 2017 Planned number of patients changed from 235 to 120.
    • 08 Aug 2017 According to a Bellicum Pharmaceuticals media release, the company expects to report top-line results this study and a planned observational trial in pediatric patients receiving transplants from matched unrelated donors (MUD) without BPX-501 in the second half of 2018 with MAA filings planned for 2019.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top